Previous reports have proposed that the increased GM-CSF levels in nonobese diabetic (NOD) mice and T1D patients may represent the organisms’ efforts to compensate for the defective responses of the hematopoietic cells (including bone marrow-derived DCs and pancreatic macrophages) to this growth factor [29,30]. The gene discussed is CSF2; the disease is type 1 diabetes mellitus.